Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision

IMPORTANCE: Melanoma in situ (MIS) is increasing in incidence, and expert consensus opinion recommends surgical excision for therapeutic management. Currently, wide local excision (WLE) is the standard of care. However, Mohs micrographic surgery (MMS) is now used to treat a growing subset of individ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA dermatology (Chicago, Ill.) Ill.), 2017-05, Vol.153 (5), p.436-441
Hauptverfasser: Nosrati, Adi, Berliner, Jacqueline G, Goel, Shilpa, McGuire, Joseph, Morhenn, Vera, de Souza, Juliana R, Yeniay, Yildiray, Singh, Rasnik, Lee, Kristina, Nakamura, Mio, Wu, Rachel R, Griffin, Ann, Grimes, Barbara, Linos, Eleni, Chren, Mary Margaret, Grekin, Roy, Wei, Maria L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:IMPORTANCE: Melanoma in situ (MIS) is increasing in incidence, and expert consensus opinion recommends surgical excision for therapeutic management. Currently, wide local excision (WLE) is the standard of care. However, Mohs micrographic surgery (MMS) is now used to treat a growing subset of individuals with MIS. During MMS, unlike WLE, the entire cutaneous surgical margin is evaluated intraoperatively for tumor cells. OBJECTIVE: To assess the outcomes of patients with MIS treated with MMS compared with those treated with WLE. DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of a prospective database. The study cohort consisted of 662 patients with MIS treated with MMS or WLE per standard of care in dermatology and surgery (general surgery, otolaryngology, plastics, oculoplastics, surgical oncology) at an academic tertiary care referral center from January 1, 1978, to December 31, 2013, with follow-up through 2015. EXPOSURE: Mohs micrographic surgery or WLE. MAIN OUTCOMES AND MEASURES: Recurrence, overall survival, and melanoma-specific survival. RESULTS: There were 277 patients treated with MMS (mean [SD] age, 64.0 [13.1] years; 62.1% male) and 385 treated with WLE (mean [SD] age, 58.5 [15.6] years; P 
ISSN:2168-6068
2168-6084
DOI:10.1001/jamadermatol.2016.6138